Loading company…
SignDo develops tumor-targeted fluorescent contrast agents for fluorescence-guided surgery.
Founded in 2021 and based in Suzhou, China, SIGNDO Biotechnology (Suzhou) Co., Ltd., doing business as SignDo, develops tumor-targeted fluorescent contrast agents. Its RT-TFC™ R&D platform supports development of Fluorescence-Drug Conjugates for fluorescence-guided surgery. In February 2026, the company raised Series A funding from Leader Venture Capital and OTHER to support product development, clinical trials, and industrialization.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in